News/ News/ Sales and Marketing Novartis takes aim at MS blockbuster Tysabri in US and Europe Phil Taylor Biogen, biosimilar, Novartis, Sandoz, Tysabri 0 Comment Regulators in the US and Europe have started to review Novartis’ biosimilar version of Biogen’s big-selling multiple sclerosis Share X Novartis takes aim at MS blockbuster Tysabri in US and Europe https://pharmaphorum.com/news/novartis-takes-aim-at-ms-blockbuster-tysabri-in-us-and-europe/
News/ News/ Sales and Marketing Polpharma in pole position for biosimilar Tysabri in Europe Phil Taylor Biogen, biosimilar, Polpharma, Sandoz, Tysabri 0 Comment Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version Share X Polpharma in pole position for biosimilar Tysabri in Europe https://pharmaphorum.com/news/polpharma-in-pole-position-for-biosimilar-tysabri-in-europe/
News/ News/ Sales and Marketing AbbVie’s Humira tops ICER’s list of unwarranted price hikes again Phil Taylor AbbVie, Biogen, Humira, ICER, medicines spending, Novartis, pricing, Promacta, Tysabri, US 0 Comment With drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and Share X AbbVie’s Humira tops ICER’s list of unwarranted price hikes again https://pharmaphorum.com/news/abbvies-humira-tops-icers-list-of-unwarranted-price-hikes-again/
Market Access/ News/ News/ News/ R&D/ R&D Tysabri failure in stroke a setback for Biogen Andrew McConaghie Biogen, CNS, neurology, stroke, Tysabri 0 Comment Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed. Share X Tysabri failure in stroke a setback for Biogen https://pharmaphorum.com/news/tysabri-failure-stroke-setback-biogen/
